Trump-Zelensky meeting ahead, Fed rate outlook in focus - what’s moving markets
Investing.com - GeneDx Holdings (NASDAQ: WGS) reported fourth quarter EPS of $0.08, $0.56 better than the analyst estimate of $-0.48. Revenue for the quarter came in at $95.3M versus the consensus estimate of $61.7M.
Guidance
GeneDx Holdings sees FY 2025 revenue of $350.00M-$360.00M versus the analyst consensus of $338.80M.
GeneDx Holdings’s stock price closed at $76.35. It is down -3.00% in the last 3 months and up 1.41K% in the last 12 months.
GeneDx Holdings saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See GeneDx Holdings’s stock price’s past reactions to earnings here.
According to InvestingPro, GeneDx Holdings’s Financial Health score is "good performance".
Check out GeneDx Holdings’s recent earnings performance, and GeneDx Holdings’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar